Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals (TARS) has filed zero red-flag 8-Ks and reported zero cyber incidents over the past 90 days, signaling operational stability in the near term. However, low event frequency in a short window does not indicate absence of structural risk; the company's equity story, financing trajectory, and shareholder dilution profile require deeper analysis. The full $49 Report extends the lookback to 12 months of SEC filings, quantifies dilution risk, maps financing history, and surfaces AI-detected risk signals invisible to standard screeners. The full $49 Report adds dilution risk scoring, historical 8-K context, capitalization trends, and machine-flagged anomalies across the complete filing record.